Abstract
AimWe conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long‐acting injectable second‐generation antipsychotic (LAI‐SGA) therapy due to adverse events (AEs).MethodsThe study included patients with schizophrenia and related psychotic disorders who commenced LAI‐SGA therapy between January/1//2009 and March/31/2020 at Fujita Health University Hospital in Toyoake, Japan.ResultsWe conducted a chart review of 157 patients with schizophrenia. At the time of this survey, 4 (6.9%), 5 (12.2%), and 10 (17.2%) of the patients in the aripiprazole once monthly, paliperidone palmitate, and risperidone‐LAI groups, respectively, discontinued due to AEs since the start of LAI‐SGA therapy. Three patients required hospitalization for AE treatment.ConclusionThe severity of these AEs in most patients is moderate (ie, no hospital treatment required). Due to the small sample size, a larger study is needed to confirm/replicate our study results.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
